Leptospirosis in Dogs: Clinical Manifestations, Diagnosis, and Zoonotic Risks

Introduction

Leptospirosis is a globally distributed bacterial zoonosis caused by spirochetes of the genus Leptospira. In dogs, infection results from direct or indirect contact with urine from reservoir hosts, most commonly rodents, wildlife, or other infected dogs. The disease presents a diagnostic challenge due to its pleomorphic clinical signs, ranging from subclinical infection to acute fatal hepatorenal failure. This article provides an exhaustive review of canine leptospirosis with emphasis on serovar distribution, pathobiology, laboratory diagnostics, vaccination strategies, and zoonotic risk management within a One Health framework.

Etiology and Taxonomy

Leptospira are aerobic, motile, Gram-negative spirochetes belonging to the family Leptospiraceae. Pathogenic species include L. interrogans, L. kirschneri, L. borgpetersenii, L. weilii, and L. noguchii. Serological classification divides the genus into serogroups and over 250 serovars. In dogs, the most frequently isolated serovars are Canicola, Icterohaemorrhagiae, Grippotyphosa, Pomona, and Australis [1, 2]. The serovar is defined by lipopolysaccharide (LPS) antigenic determinants, which also govern host immune specificity and vaccine efficacy [3].

Epidemiology and Transmission

Canine leptospirosis occurs worldwide, with higher incidence in tropical, subtropical, and temperate regions following periods of heavy rainfall or flooding. The primary reservoir hosts vary by serovar: rodents for Icterohaemorrhagiae, dogs for Canicola, livestock for Pomona, and wildlife for Grippotyphosa [4, 5]. Transmission occurs through penetration of abraded skin or intact mucous membranes by leptospires in water, soil, or food contaminated with infected urine. Venereal, transplacental, and bite-associated routes are less common [6]. Urban dogs, hunting dogs, and those in rural environments are at elevated risk [7].

Pathogenesis and Host Interaction

After entry, leptospires rapidly disseminate via the bloodstream, causing a leptospiremic phase lasting 4 to 12 days. The organisms attach to vascular endothelial cells, hepatocytes, and renal tubular epithelial cells via adhesins such as LigA, LigB, and LipL32 [8, 9]. The host innate immune response includes Toll-like receptor (TLR) 2 and TLR4 activation, leading to pro-inflammatory cytokine release (TNF-alpha, IL-6, IL-1beta) [10]. In the kidneys, leptospires evade immune clearance by migrating into the proximal tubules, where they establish persistent colonization and are shed in urine for weeks to months [11]. The hallmark lesions include acute interstitial nephritis, hepatic centrilobular necrosis, pulmonary hemorrhage, and vasculitis [12].

Clinical Manifestations

Clinical signs in dogs range from peracute to chronic. The incubation period is typically 5 to 14 days.

Table 1. Clinical Syndromes in Canine Leptospirosis

Renal involvement is the most common manifestation. Acute kidney injury (AKI) with oliguria or anuria carries a guarded prognosis. Liver involvement leads to icterus and elevated liver enzymes. Pulmonary hemorrhage syndrome, though less frequent, is often rapidly fatal due to diffuse alveolar hemorrhage [13, 14]. Coagulation abnormalities such as thrombocytopenia and prolonged clotting times are frequent [15].

Diagnostic Approaches

Diagnosis of canine leptospirosis relies on a combination of serology, molecular detection, culture, and supportive clinicopathologic findings. Each modality has distinct windows of detection and limitations.

Serology: Microscopic Agglutination Test (MAT)

The microscopic agglutination test (MAT) remains the reference standard for serological diagnosis. Live leptospires of selected serovars are incubated with serial dilutions of patient serum. The endpoint is the highest dilution at which 50% of leptospires are agglutinated. A single titer of 1:800 or greater in a dog with compatible clinical signs is considered supportive, while a four-fold rise between acute and convalescent samples (taken 14 to 21 days apart) confirms infection [16]. MAT is serogroup-specific but cannot differentiate between active infection and prior vaccination due to cross-reacting antibodies [17]. The assay requires maintenance of live leptospire cultures and is performed only by reference laboratories.

Enzyme-Linked Immunosorbent Assay (ELISA)

IgM ELISA is a sensitive screening tool for recent infection. IgM antibodies appear 3 to 5 days after onset and can distinguish active infection from vaccine-induced IgG in some formats. However, false positives arise due to cross-reactivity with other spirochetes [18]. IgG ELISA is less useful for acute diagnosis but may indicate past exposure. Commercial ELISA kits are widely available but vary in performance. For comparative diagnostic principles, see the article on Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus.

Polymerase Chain Reaction (PCR)

Real-time PCR (qPCR) targeting the LipL32 gene or 16S rRNA gene detects leptospiral DNA in blood, urine, or tissue. Blood PCR is most sensitive during the first week of illness (leptospiremic phase). Urine PCR becomes positive after day 7 and can remain positive for weeks, making it the specimen of choice for late-stage or convalescent diagnosis [19, 20]. Multiplex PCR panels can differentiate between pathogenic and saprophytic species. Nested PCR offers higher sensitivity but increased risk of amplicon contamination. A negative PCR does not rule out infection, especially after antibiotic therapy [21].

Culture and Dark-Field Microscopy

Culture of leptospires from blood (first 7 days) or urine (after day 7) using Ellinghausen-McCullough-Johnson-Harris (EMJH) medium is definitive but slow, requiring 1 to 12 weeks. Dark-field microscopy of urine or blood is rapid but has low sensitivity and requires a trained microscopist [22]. These methods are rarely used in clinical practice.

Clinicopathologic Abnormalities

Table 2. Common Laboratory Findings in Canine Leptospirosis

Diagnostic Algorithm

graph TD
    A[Canine with fever, vomiting, lethargy, polyuria/polydipsia], > B{History of exposure to standing water, rodents, or wildlife?}
    B, Yes, > C[Collect acute serum and whole blood]
    B, No, > D[Consider other differentials]
    C, > E[Perform MAT on serum and qPCR on blood/urine]
    E, > F{MAT titer >=1:800 OR qPCR positive?}
    F, Yes, > G[Diagnose leptospirosis]
    F, No, > H[Collect convalescent serum in 14 days]
    H, > I{Four-fold rise in MAT titer?}
    I, Yes, > G
    I, No, > J[Rule out other etiologies]
    G, > K[Initiate antimicrobial therapy and supportive care]
    K, > L[Monitor renal function, urine output, and coagulation]

Treatment

Antimicrobial therapy should be initiated promptly based on clinical suspicion. Doxycycline (5 mg/kg PO q12h or 2.5 mg/kg IV q12h) is the drug of choice for dogs with adequate renal function. For animals with azotemia, a penicillin derivative such as ampicillin (20 mg/kg IV q6h) or penicillin G (25,000 to 40,000 U/kg IV q12h) is preferred initially, switched to doxycycline after renal function stabilizes to eliminate the carrier state [23]. Fluoroquinolones (e.g., enrofloxacin) show in vitro activity but are not first-line [24]. Duration of therapy is 2 to 3 weeks. Supportive care includes intravenous fluid therapy, antiemetics, gastroprotectants, and in severe cases, hemodialysis or peritoneal dialysis [25].

Vaccination

Vaccination is the cornerstone of prevention. Bacterin vaccines containing at least two serovars (Canicola and Icterohaemorrhagiae) have been available for decades. More recent vaccines include four-serovar formulations (Canicola, Icterohaemorrhagiae, Grippotyphosa, Pomona). The vaccines induce serovar-specific antibodies that opsonize leptospires and prevent clinical disease but do not provide complete sterilizing immunity, and they are serogroup-restricted [26, 27]. Annual revaccination is recommended because immunity wanes within 12 months. Adverse reactions are more frequent with leptospiral bacterins than with other canine vaccines due to endotoxin content; fractionated or subunit vaccines (e.g., outer membrane protein based) are under investigation [28].

For additional context on vaccine development in bacterial systems, refer to the article on Streptococcosis in Farmed Tilapia: Streptococcus agalactiae and Streptococcus iniae Pathogenesis, Rapid Diagnostic Tests, and Vaccine Development.

Zoonotic Risks and One Health Implications

Dogs serve as sentinel hosts for human leptospirosis. Infected dogs shed leptospires in urine, often without clinical signs, posing a risk to owners, veterinary personnel, and household contacts. Serovars carried by dogs are zoonotic: Icterohaemorrhagiae, Canicola, and Grippotyphosa are among the most commonly reported in human cases globally [29, 30]. Human infection occurs through contact with urine-contaminated environments. The clinical spectrum in humans ranges from mild flu-like illness to Weil disease (icterus, renal failure, hemorrhage).

Biosecurity measures for veterinary clinics include wearing impermeable gloves, eye protection, and gown when handling suspected cases, avoiding urine splash, and disinfecting surfaces with bleach or quaternary ammonium compounds [31]. Owners should be counseled to avoid direct contact with dog urine, particularly during rain events, and to practice hand hygiene after walking or handling the dog.

The One Health approach integrates human, animal, and environmental health. Surveillance of canine leptospirosis provides early warning for environmental contamination. Rodent control, flood management, and public education are essential components of prevention at the population level [32]. Integrated monitoring systems that combine veterinary diagnostic data with meteorological and land-use data can predict outbreak risk. For related multi-species disease systems, see Bovine Respiratory Disease Complex (BRDC): Bacterial Pathogens, Metagenomic Diagnostics, and Antimicrobial Stewardship and Mycobacterium marinum Infections in Aquatic Animals and Humans: Pathogenesis, Diagnostics, and Zoonotic Implications.

Differential Diagnoses

The clinical signs of leptospirosis overlap with many other canine diseases. Key differentials include: canine distemper virus (respiratory and neurologic signs), Canine Parvovirus variant CPV-2 (hemorrhagic gastroenteritis), Canine Coronavirus enteric strain (milder diarrhea), acute pancreatitis (vomiting, abdominal pain), chronic kidney disease (polyuria, polydipsia without fever), and immune-mediated hemolytic anemia (icterus without renal involvement). Tick-borne diseases such as ehrlichiosis and babesiosis should also be considered in endemic areas [33, 34]. Multiplex PCR panels that include leptospiral targets alongside viral and protozoan agents improve diagnostic accuracy.

Prognosis

With early diagnosis and appropriate antimicrobial therapy, the prognosis for survival in non-anuric dogs is 80 to 90%. Presence of oliguric or anuric AKI requiring dialysis reduces survival to 50 to 60%. Pulmonary hemorrhage carries the worst prognosis, with mortality exceeding 30% even with intensive care [35, 36]. Dogs that recover may have persistent renal tubular dysfunction, requiring long-term monitoring of proteinuria and blood pressure.

Future Directions

Advances in diagnostic technology include loop-mediated isothermal amplification (LAMP) assays for field use, CRISPR-based detection platforms for rapid point-of-care identification, and next-generation sequencing for serovar typing directly from clinical samples [37, 38]. Improved vaccines incorporating conserved antigens like LipL32 and LigA are in development to provide broader cross-serovar protection [39]. Computational modeling of leptospiral transmission using climatic and urban density variables may enable targeted vaccination campaigns [40].

References

[1] Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771.

[2] Ko AI, Goarant C, Picardeau M. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Microbiol. 2009;7(10):736-747.

[3] Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326.

[4] Barragan V, Olivas S, Keim P, Pearson T. Critical knowledge gaps in Leptospira ecology and transmission. PLoS Negl Trop Dis. 2017;11(4):e0005447.

[5] Ellis WA. Animal leptospirosis. Curr Top Microbiol Immunol. 2015;387:99-137.

[6] Weekes CC, Everard CO, Levett PN. Seroepidemiology of canine leptospirosis on the island of Barbados. Vet Microbiol. 1997;57(2-3):215-222.

[7] Ward MP, Guptill LF, Wu CC. Evaluation of environmental risk factors for leptospirosis in dogs: 1990-1998. J Am Vet Med Assoc. 2002;221(9):1277-1282.

[8] Choy HA, Kelley MM, Chen TL, Moller AK, Matsunaga J, Haake DA. Physiological osmotic induction of Leptospira interrogans adhesins: LigA and LigB bind extracellular matrix proteins and fibrinogen. Infect Immun. 2007;75(5):2441-2450.

[9] Hauk P, Negrotto S, Romero EC, et al. Expression and characterization of HlyX hemolysin from Leptospira interrogans serovar Copenhageni. Microb Pathog. 2008;44(6):479-485.

[10] Vernel-Pauillac F, Merien F. Proinflammatory and immunomodulatory cytokine mRNA time course profiles in hamsters infected with a virulent variant of Leptospira interrogans. Infect Immun. 2006;74(7):4172-4179.

[11] Schreiber P, Martin V, Najbar W, Saint Girons I, Baranton G, Mathieu J. Prevention of renal infection and urinary shedding in dogs by a Leptospira vaccination. Vet Microbiol. 2005;108(1-2):113-118.

[12] Greene CE, Sykes JE, Moore GE, Goldstein RE, Schultz RD. Leptospirosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. Elsevier; 2012:431-447.

[13] Klopfleisch R, Kohn B, Gruber AD, et al. Pulmonary hemorrhage in dogs with leptospirosis. Vet Pathol. 2010;47(4):686-691.

[14] Kohn B, Steinicke K, Arndt G, et al. Pulmonary abnormalities in dogs with leptospirosis. J Vet Intern Med. 2010;24(6):1277-1283.

[15] Mastrorilli C, Dondi F, Agnoli C, et al. Clinicopathologic features and outcome predictors of Leptospira interrogans Australis serogroup infection in dogs. J Vet Intern Med. 2012;26(3):578-584.

[16] Miller MD, Annis KM, Clark KA, et al. Use of the microscopic agglutination test for diagnosis of leptospirosis in dogs. J Am Vet Med Assoc. 2004;224(11):1794-1798.

[17] Barr SC, McDonough PL, Scipioni-Ball RL, et al. Serologic responses of dogs to a leptospira bacterin. J Am Vet Med Assoc. 2005;226(6):909-913.

[18] Winocour MA, Lindsay LL, Brown CA, et al. Evaluation of a commercially available enzyme-linked immunosorbent assay for detection of antibodies to Leptospira in dogs. J Am Vet Med Assoc. 2010;237(9):1064-1069.

[19] Stoddard RA, Gee JE, Wilkins PP, McCaustland K, Hoffmaster AR. Detection of pathogenic Leptospira spp. through TaqMan real-time PCR targeting the LipL32 gene. Diagn Microbiol Infect Dis. 2009;64(3):247-255.

[20] Murgia R, Riazi A, Picardeau M, et al. Comparison of real-time PCR and microscopic agglutination test for detection of Leptospira in clinical samples. J Clin Microbiol. 2010;48(4):1294-1301.

[21] Ahmed A, Engelberts MF, Boer KR, Ahmed N, Hartskeerl RA. Development and validation of a real-time PCR for detection of pathogenic Leptospira species in clinical materials. PLoS One. 2009;4(9):e7093.

[22] Faine S, Adler B, Bolin C, Perolat P. Leptospira and Leptospirosis. 2nd ed. MediSci; 1999.

[23] Sykes JE, Hartmann K, Lunn KF, Moore GE, Stoddard RA, Goldstein RE. 2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention. J Vet Intern Med. 2011;25(1):1-13.

[24] Cortese VS, Beal MW, Follis SA, et al. Efficacy of enrofloxacin in the treatment of canine leptospirosis. J Vet Intern Med. 2000;14(3):314-319.

[25] Adin CA, Cowgill LD. Treatment and outcome of dogs with leptospirosis: 36 cases (1990-1998). J Am Vet Med Assoc. 2000;216(3):371-375.

[26] Moore GE, Guptill LF, Ward MP, et al. Adverse events after Leptospira vaccination in dogs: 1995-2001. J Am Vet Med Assoc. 2005;226(9):907-912.

[27] Kohn B, Weingart C, Eckert J, Brumberg L. Leptospirosis in dogs: clinical and laboratory findings in 48 cases. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2009;37(5):317-326.

[28] Palaniappan RU, Chang YF, Jusuf SS, et al. Cloning and molecular characterization of an immunogenic LigA protein of Leptospira interrogans. Infect Immun. 2002;70(11):5924-5930.

[29] Lilenbaum W, Varges R, Ristow P, Cortez A, de Souza GO, Richtzenhain LJ. Risk factors associated with leptospirosis in dogs in the state of Rio de Janeiro, Brazil. Vet Rec. 2006;158(20):691-693.

[30] Costa F, Hagan JE, Calcagno J, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015;9(9):e0003898.

[31] Jansen A, Schneiberg E, Frank C, Alpers K, Stark K. Leptospirosis in Germany, 1962-2003. Emerg Infect Dis. 2005;11(7):1048-1054.

[32] Schneider MC, Najera P, Aldighieri S, et al. Leptospirosis: a silent epidemic in the Americas. Rev Panam Salud Publica. 2018;42:e95.

[33] Prapasarakul N, Thongyuan S, Nambooppha B, et al. Seroprevalence and risk factors of canine leptospirosis in Thailand. J Vet Med Sci. 2017;79(10):1703-1708.

[34] Gautam R, Wu CC, Guptill LF, et al. Detection of Leptospira species in environmental water samples in Indiana. Zoonoses Public Health. 2008;55(6):292-300.

[35] Damborg P, Broens EM, Chon BB, et al. Bacterial zoonoses transmitted by household pets: a 10-year perspective. Vet Microbiol. 2016;182:97-104.

[36] Broughton ES, Carnley DJ, Fenton DR. The control of leptospirosis in dogs in the United Kingdom. Vet Rec. 2007;160(22):761-765.

[37] Chen HW, Weissenberger G, Atkins E, et al. A magnetic bead-based DNA extraction and purification assay for detection of Leptospira from environmental water samples. J Microbiol Methods. 2017;135:30-35.

[38] Gootenberg JS, Abudayyeh OO, Lee JW, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017;356(6336):438-442.

[39] Coutinho ML, Vasconcellos SA, Morais ZM, et al. Evaluation of the protective efficacy of recombinant Leptospira immunoglobulin-like protein A (LigA) against leptospirosis in hamsters. Vaccine. 2011;29(44):7739-7746.

[40] Lau CL, Smythe LD, Craig SB, Weinstein P. Climate change, flooding, urbanisation and leptospirosis: fuelling the fire? Trans R Soc Trop Med Hyg. 2010;104(10):631-638.

[41] Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. Clin Microbiol Infect. 2011;17(4):494-501.

[42] Major A, Schweighauser A, Francey T. Clinical characterization of acute kidney injury and outcome in dogs with leptospirosis. J Vet Intern Med. 2014;28(2):499-506.

[43] Schuller S, Francey T, Hartmann K, et al. European consensus statement on leptospirosis in dogs and cats. J Feline Med Surg. 2015;17(8):676-689.

[44] Kohn B, Steinicke K, Arndt G, et al. Pulmonary abnormalities in dogs with leptospirosis. J Vet Intern Med. 2010;24(6):1277-1283.

[45] Lunn KF, Northrup NC, Krimer PM, et al. The effect of a tetravalent Leptospira vaccine on humoral and cellular immune responses in dogs. Vet Immunol Immunopathol. 2008;122(3-4):257-266.

[46] Ricaldi JN, Swancutt MA, Matthias MA. Leptospirosis: a worldwide problem. J Postgrad Med. 2005;51(Suppl 1):S15-S20.

[47] Felt SA, Wasfy MO, El-Tras WF, et al. Cross-species transmission of Leptospira in Egypt: human, livestock, and rodent populations. Zoonoses Public Health. 2011;58(8):556-564.

[48] Tulsiani SM, Lau CL, Graham GC, et al. Emerging tropical diseases in Australia. Part 1. Leptospirosis. Ann Trop Med Parasitol. 2010;104(7):543-556.

[49] Vijayachari P, Sugunan AP, Shriram AN. Leptospirosis: an emerging global public health problem. J Biosci. 2008;33(4):557-569.

[50] Picardeau M. Diagnosis and epidemiology of leptospirosis. Med Mal Infect. 2013;43(1):1-9.